<DOC>
	<DOCNO>NCT00512239</DOCNO>
	<brief_summary>Inflammatory joint disease major cause invalidity morbidity . Rheumatoid arthritis ( RA ) , frequent chronic arthritides , affect close 1 % Canadian population . Direct indirect cost RA represent close 1 % gross national product . Recent evidence suggest initiation early ( e.g. , first 3-12 month disease ) aggressive treatment decrease mortality long term invalidity RA chronic arthritides . However , significant proportion patient early polyarthritis ( EPA ) benign evolution , even fulfill criterion RA . On contrary , patient whose arthritis persist 12 month progressive destructive disease . Currently available clinical , serological genetic marker severity arthritic patient perform poorly EPA patient identify patient whose arthritis likely persist thus deserve aggressive treatment . The Investigators propose prospective longitudinal study define contribution detection rheumatoid arthritis-specific autoantibody ( RASA ) , either alone combination marker severity , prognostic evaluation patient present EPA . Availability effective serological tool establish prognosis individual patient would improve therapeutic decision clinical practice . The prognostic tool would represent powerful instrument subset patient homogeneous group clinical trial , increase power .</brief_summary>
	<brief_title>Prognostic Evaluation Inflammatory Polyarthritis Recent Onset</brief_title>
	<detailed_description>Inflammatory polyarthritides major cause invalidity morbidity . Treatment rheumatoid arthritis ( RA ) , common severe disease , clearly effective initiate early use aggressive therapeutic protocol . The recent availability effective extremely costly biologic agent may improve treatment strategy . Specific arthritides ( e.g. , RA ) define use set criterion unable define prognosis use select patient , early course disease , treat aggressively . A number putative prognostic marker severity available , include anti-Sa anti-Cyclic Citrullinated peptide ( Anti-CCP ) antibody ( Abs ) , whose presence highly specific RA . Anti-Cit Abs might characterize one severe subset RA , clinically pathogenically . However , marker yet demonstrate risk-stratify patient arthritis recent onset . Objectives . Our PRIMARY objective evaluate sensitivity , specificity , positive likelihood ratio ( +LR ) anti-Sa Abs identify among patient early polyarthritis ( EPA ) first 12 month disease ( median 4 month ) , 18 , 30 , 42 60 month disease : 1- persistent arthritis ; 2- satisfy American College Rheumatology ( ACR ) criteria RA ; 3- developed SEVERE disease ( define Sharp/van der Heijde radiological score modify Health Assessment Questionnaire ( M-HAQ ) score , well composite index include score ) . In particular , want evaluate size ADDITIONAL independent contribution anti-Sa Abs predict severe disease , add marker poor prognosis establish RA ( e.g. , immunoglobulin M ( IgM ) Rheumatoid Factor ( RF ) , `` share epitope '' , persistent high C-Reactive Protein ( CRP ) level ) . Our SECONDARY objective evaluate sensitivity , specificity , +LR : 1- anti-CCP anti-Sa Abs ( individually set ) identify among patient EPA develop SEVERE disease 18 , 30 , 42 , 60 month ; 2- novel genetic marker identify among patient EPA develop SEVERE disease 18 , 30 , 42 , 60 month ; 3- anti-Sa anti-CCP Abs identify among patient EPA patient require intensive anti-rheumatic treatment ( DMARD combination and/or biologics ) 18 , 30 , 42 60 month ; 4- serum urine marker cartilage degradation regeneration identify among patient EPA develop SEVERE disease 18 , 30 , 42 , 60 month . Methods . We set single-center longitudinal observational study ( LOS ) plan include 390 consecutive EPA patient observe 5 year . EPA define synovitis affect 3 joint one month le 12 month , specific exclusion . At inclusion , pre-defined time point disease onset , extensive ( focus ) demographic , clinical , serological , radiological genetic data collect , without interference treatment . Treating physicians patient remain uninformed status patient regard research data ( genomic data , anti-Sa anti-CCP Abs ) . About 250 patient include time renewal . Loss follow ( V4 patient ) visit 5 % mostly find patient remission . Data collect use verify whether patient reach predefined outcome include remission , persistence arthritis , persistence arthritis fulfil RA criterion , DMARD use , SEVERE disease . Discussion . We assemble large cohort patient EPA thoroughly reassess regular interval , allow stratification patient use outcome measure set advance . The information gain study may significant therapeutic economic implication .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Early Rheumatoid arthritis Early Inflammatory Arthritis Refusal inability consent Infectious arthritis Microcrystalline arthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Early Rheumatoid Arthritis</keyword>
	<keyword>Early inflammatory arthritis</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Autoantibodies</keyword>
	<keyword>Anti-Sa antibody</keyword>
	<keyword>Anti-CCP antibody</keyword>
</DOC>